Related Experiment Videos
[Colorectal cancer: current treatment options]
U Graeven1, N Andre, W Schmiegel
1Medizinische Klinik I, Kliniken Maria Hilf GmbH, Krankenhaus St. Franziskus, Mönchengladbach. innere1@mariahilf.de
Zeitschrift Fur Gastroenterologie
|December 14, 2004
Summary
Colorectal cancer survival is improving with new chemotherapy drugs like Irinotecan and Oxaliplatin, and targeted therapies. These advancements offer better outcomes for patients, though treatment strategies are becoming more complex.
Area of Science:
- Oncology
- Gastroenterology
Background:
- Colorectal cancer is a major cause of cancer death globally, with a 5-year survival rate of 50-60% despite surgical curability in 70-80% of cases.
- Adjuvant therapy has become crucial in treating colorectal cancer over the past decade.
- New chemotherapeutic agents and targeted therapies are significantly improving patient outcomes.
Purpose of the Study:
- To review current treatment strategies for colorectal cancer.
- To discuss the impact of novel chemotherapies and targeted agents on patient survival and treatment complexity.
Main Methods:
- Review of recent clinical studies and advancements in colorectal cancer treatment.
- Analysis of the efficacy of new chemotherapeutic agents (Irinotecan, Oxaliplatin) and targeted therapies (monoclonal antibodies).
Main Results:
- New chemotherapies have increased tumor response and median survival in colorectal cancer patients.
- Sequential combination therapies can extend survival beyond 20 months.
- Targeted therapies show promising effects by manipulating molecular tumor mechanisms.
Conclusions:
- Modern colorectal cancer treatment involves increasingly complex choices and strategies.
- Ongoing research and development of new drugs are enhancing treatment efficacy and patient survival.